Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3637-3640

  Liou, Bo Huang ^a   Lee, Yi Tzu ^b,c   Kuo, Shu Chen ^b,c,d   Liu, Po Yu ^e   Fung, Chang Phone ^b,c  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; SULBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; END STAGE RENAL DISEASE; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE; VERY ELDERLY; ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTIONS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; RETROSPECTIVE STUDIES;

EID: 84929648571     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04987-14     Document Type: Article

References (10)

1. Gardiner D, Dukart G, Cooper A, Babinchak T. 2010. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 50:229-238. http://dx.doi.org/10.1086/648720.
2. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. 2005. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41(Suppl):S341-S353. http://dx.doi.org/10.1086/431675.
3. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. 2005. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41(Suppl):S354-S367. http://dx.doi.org/10.1086/431676.
4. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R. 2009. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 63:52-61. http://dx.doi.org/10.1016/j.diagmicrobio.2008.09.001.
5. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R. 2008. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 61:329-338. http://dx.doi.org/10.1016/j.diagmicrobio.2008.04.009.
6. Lee YT, Kuo SC, Yang SP, Lin YT, Tseng FC, Chen TL, Fung CP. 2012. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 55:209-215. http://dx.doi.org/10.1093/cid/cis385.
7. U.S. Food and Drug Administration. 2013. Tygacil (tigecycline): drug safety communication - increased risk of death. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedical-Products/ucm370170.htm.
8. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. 2011. Predictors of mortality in patients with bloodstream infections caused by KPCproducing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17:1798-1803. http://dx.doi.org/10.1111/j.1469-0691.2011.03514.x.
9. Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, Chang SC. 2011. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis 52:352-360. http://dx.doi.org/10.1093/cid/ciq154.
10. Lee YC, Huang YT, Tan CK, Kuo YW, Liao CH, Lee PI, Hsueh PR. 2011. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother 66:1839-1846. http://dx.doi.org/10.1093/jac/dkr200.